BLISSGVS
BLISS GVS PHARMA LTD
Each stock's 10,000-path forecast, rendered as light.
BLISS GVS PHARMA LTD (BLISSGVS) Stock Analysis & Case Study
Is BLISSGVS a good buy? The data-driven verdict.
BLISS GVS PHARMA LTD (BLISSGVS) trades at ₹478,on the numbers it tread carefully, a Downstox Snapshot Score of 34/100.
On the numbers, BLISS GVS PHARMA LTD (BLISSGVS) tread carefully, a Downstox Snapshot Score of 34/100, weighing premium at 38.5× earnings, ROE of 11.8%, a 46% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
BLISSGVS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How BLISSGVS ranks against the 2,371 companies in our screener
- BLISSGVS's market cap of 5,074 Cr ranks in the 66th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- BLISSGVS's book value of ₹113 ranks in the 56th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- BLISSGVS's promoter holding of 35.0% ranks in the 12th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- BLISSGVS's 3-year profit (PAT) growth of 23.0% ranks in the 60th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- BLISSGVS's 3-year revenue growth of 7.0% ranks in the 41st percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- BLISSGVS's debt-to-equity ratio of 0.02x is lower than 94% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
Is BLISSGVS overvalued? BLISSGVS P/E vs peers
BLISSGVS trades at 38.5× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
BLISSGVS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of BLISSGVS history (14%/yr drift, 57%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| BLISSGVS 2027 | ₹216 | ₹450 | ₹938 | -6% |
| BLISSGVS 2028 | ₹151 | ₹424 | ₹1,187 | -11% |
| BLISSGVS 2029 | ₹110 | ₹399 | ₹1,451 | -16% |
| BLISSGVS 2030 | ₹86 | ₹376 | ₹1,640 | -21% |
| BLISSGVS 2031 | ₹70 | ₹354 | ₹1,793 | -26% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability BLISSGVS goes up, or doubles?
The bull case for BLISSGVS
- BLISS GVS PHARMA LTD is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,451.
The bear case & risks
- BLISSGVS's P/E of 38.5x is lower than 35% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- BLISSGVS's return on equity of 11.8% ranks in the 58th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- High historical volatility (57%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹110.
BLISSGVS volatility & expected range, how bumpy is the ride?
Over the last 9.8 years BLISSGVS compounded at 14%/year with annualized volatility of 57%. That volatility implies a 1-year 80% range of ₹216-₹938, the honest backbone behind any single price target.
BLISSGVS price forecast, the full 60-month probability fan
BLISSGVS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds BLISSGVS hits common targets within the simulated horizon?
Full multi-horizon detail on the BLISSGVS price target & forecast page.
BLISSGVS Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. BLISSGVS scores 6/8, mixed financial health.
BLISSGVS MTF margin & leverage across 2 brokers
Margin Trading Facility lets you buy BLISSGVS with part of the capital. Lower margin % = higher leverage. Rates compared across 2 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| FyersCHEAPEST | 100.00% | 1.0× |
| Anand RathiCHEAPEST | 100.00% | 1.0× |
Compare every broker on the BLISSGVS MTF page.
About BLISS GVS PHARMA LTD: sector, index & market-cap context
BLISS GVS PHARMA LTD (BLISSGVS) is a small-cap NSE-listed company, with a market capitalisation of ₹5,074 Cr. See more stocks on our screener.
How the BLISSGVS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of BLISS GVS PHARMA LTD's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
BLISSGVS analysis, FAQs
Is BLISS GVS PHARMA LTD (BLISSGVS) a good buy?
On the numbers, BLISS GVS PHARMA LTD (BLISSGVS) tread carefully, a Downstox Snapshot Score of 34/100, weighing premium at 38.5× earnings, ROE of 11.8%, a 46% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is BLISSGVS overvalued or undervalued?
BLISSGVS trades at 38.5× earnings, premium versus the ~22× long-run Nifty average.
What is the BLISSGVS share price target for 2031?
BLISSGVS's probability-weighted 2031 median target is ₹354, with an 80% range of ₹70-₹1,793 (10,000-path Monte-Carlo).
What is the probability BLISSGVS doubles in 5 years?
The modelled probability of BLISSGVS reaching ₹955 (2×) within 5 years is 21%.
What is the bull case for BLISSGVS?
BLISS GVS PHARMA LTD is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in BLISSGVS?
BLISSGVS's P/E of 38.5x is lower than 35% of the 2,371 NSE companies in our screener, as of 8 Aug 2026. BLISSGVS's return on equity of 11.8% ranks in the 58th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026. High historical volatility (57%/yr) means a wide, bumpy range of outcomes, size positions accordingly.